Achieve Life Sciences (ACHV) Other Non-Current Assets (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Other Non-Current Assets of $265000.0 in Q1 2026, up 409.62% on a QoQ basis from $52000.0 in Q4 2025, and down 11.67% year-over-year from $300000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Other Non-Current Assets across 17 years of filings, most recently posting $265000.0 for Q1 2026.
- Quarterly Other Non-Current Assets fell 11.67% year-over-year to $265000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265000.0 (down 11.67% YoY) and the FY2025 annual result came in at $52000.0, up 33.33% from the prior year.
- Other Non-Current Assets grew to $265000.0 in Q1 2026, from $52000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $304000.0 in Q3 2024 and troughed at $39000.0 in Q4 2024.
- A 5-year average of $141705.9 and a median of $94000.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 310.81% — and 2025, when it plunged 78.62%.
- Tracing ACHV's Other Non-Current Assets over 5 years: stood at $66000.0 in 2022, then surged by 39.39% to $92000.0 in 2023, then sank by 57.61% to $39000.0 in 2024, then soared by 33.33% to $52000.0 in 2025, then soared by 409.62% to $265000.0 in 2026.
- Business Quant data shows ACHV's Other Non-Current Assets at $265000.0 in Q1 2026, $52000.0 in Q4 2025, and $65000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 304,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 92,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 66,000.00 |
| Sep 30, 2022 | 239,000.00 |
| Jun 30, 2022 | 240,000.00 |
| Mar 31, 2022 | 253,000.00 |
| Dec 31, 2021 | 183,000.00 |
| Sep 30, 2021 | 235,000.00 |
| Jun 30, 2021 | 227,000.00 |